Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Andres, Janet (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S116000, C514S302000
Reexamination Certificate
active
07999107
ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
REFERENCES:
patent: 5140031 (1992-08-01), Atwal et al.
patent: 5563170 (1996-10-01), Atwal
patent: 2004/0209902 (2004-10-01), Lin et al.
patent: 2005/0010050 (2005-01-01), Rogier et al.
patent: 2005/0272763 (2005-12-01), Toupence et al.
patent: 0499414 (1992-08-01), None
patent: 0624589 (1994-05-01), None
patent: 0600617 (1994-06-01), None
patent: 0895994 (1998-07-01), None
patent: 1357111 (2003-10-01), None
patent: 4282353 (1992-10-01), None
patent: 5032655 (1993-02-01), None
patent: WO 95/34547 (1995-12-01), None
patent: WO 98/09969 (1998-03-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 00/78724 (2000-12-01), None
patent: WO 01/49675 (2001-07-01), None
patent: WO 01/98306 (2001-12-01), None
patent: WO 03/011872 (2003-02-01), None
patent: WO 03/032897 (2003-04-01), None
patent: WO 03/055876 (2003-07-01), None
patent: WO 2004/106493 (2004-12-01), None
patent: WO 2005/000250 (2005-01-01), None
patent: WO 2005/042697 (2005-05-01), None
patent: WO 2005/047285 (2005-05-01), None
patent: WO 2006/045096 (2006-04-01), None
P. H. Reggio “Endocannabinoid structure—activity relationships for interaction at the cannabinoid receptors” Prostaglandins, Leukotrienes and Essential Fatty Acids 2002, 66, 143-160.
Lea W. Padgett “Recent developments in cannabinoid ligands” Life Sciences 2005, 77, 1767-1798.
Meurer et. al. “Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists” Bioorganic & Medicinal Chemistry Letters 15 (2005) 645-651.
Simiand et al., Behavioural Pharmacol., vol. 9 (1998), pp. 179-181, “SR 141716, a CB1 cannabinoid reeptor antagonist, selectively reduces sweet food intake . . . ”.
Debenham et al., Bioorg. & Med. Chem. Lett., vol. 16 (2006), pp. 681-685, “Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, . . . ”.
Arnone et al., Psychopharmacology, vol. 132 (1997), pp. 104-106, “Selective inhibition of sucrose and ethanol intake by SR 141716, . . . ”.
Ledent et al., Science, vol. 283 (1999), pp. 401-404, “Unresponsiveness to cannabinoids and reduced addictive effects of opiates . . . ”.
Cheer et al., Psychopharmacol., vol. 151 (2000), pp. 25-30, “Cannabinoid receptors and reward in the rat . . . ”.
Milne et al, Eur. J. Pharmacol., vol. 282 (1995), pp. 243-249, “Role of the VLA-4 integrin in leucocyte recruitment and bronchial . . . ”.
Chaperon et al., Psychopharmacol., vol. 135 (1998), pp. 324-332, “Involvement of central cannabinoid (CB1) receptors . . . ”.
Feng et al., Life Sciences, vol. 63 (1998), pp. 111-119,“Lactation increases prolactin receptor expression . . . ”.
Batkai et al., Nature Medicine, vol. 7 (2001), pp. 827-832, “Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state . . . ”.
Abraham et al., J.-Clin. Invest., vol. 93 (1994), pp. 776-787, “α4-integrins mediate antigen-induced late bronchial responses . . . ”.
Kapur, J. of Pathology, vol. 194 (2001), pp. 277-288, “Neuropathology of paediatric chronic intestinal pseudo-obstruction . . . ”.
Compton et al., J. Pharmacol. & Exper. Ther., vol. 277 (1996), pp. 586-594, “In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): . . . ”.
Tsusumi et al., Biol. Pharm. Bull. (abstract), vol. 23 (2000), pp. 657-659, “Amitripytline-induced constipation in Cynomolgus monkeys . . . ”.
Seitz et al., Tetrahedron Letters, vol. 26 (1985), pp. 4355-4358, Intramolecular Diels-Alder reactions of substituted 1,2,4,5-tetrazines and 1,2,4-triazines.
Debenham John S.
Hale Jeffrey J.
Huo Pei
Madsen-Duggan Christina B.
Walsh Thomas F.
Andres Janet
Brown Baerbel R.
Dell David K O
Merck Sharp & Dohme Corp.
Todaro John C.
LandOfFree
Substituted pyrano[2,3-B]pyridine derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrano[2,3-B]pyridine derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrano[2,3-B]pyridine derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690983